NCT01557647View on ClinicalTrials.gov

Safety and Efficacy of Inhaled Treprostinil in Patients With PAH

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2012

Primary Completion Date

December 31, 2015

Study Completion Date

June 30, 2016

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

Inhaled treprostinil

0.6mg/mL treprostinil for inhalation solution. Titrated up to 12 breaths QID.

DRUG

Placebo

placebo inhalation solution

Sponsors
All Listed Sponsors
lead

United Therapeutics

INDUSTRY